A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes

PLoS Neglected Tropical Diseases

Volumn 6, Issue 11, 2012, Pages

  de Rycker, Manu ^a   O'Neill, Sandra ^a   Joshi, Dhananjay ^a,b   Campbell, Lorna ^a   Gray, David W ^a   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b Advinus Therapeutics Private Limited Bangalore   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; DDU1; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; SURAMIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CELL COUNT; CELL DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FLUORESCENCE ANALYSIS; GROWTH CURVE; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; LIMIT OF DETECTION; NONHUMAN; TRYPANOSOMA BRUCEI;

AFRICA SOUTH OF THE SAHARA; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL VIABILITY; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI;

EID: 84870750733     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001932     Document Type: Article

References (21)

1. Malvy D, Chappuis F, (2011) Sleeping sickness. Clin Microbiol Infect 17: 986-995.
2. WHO (2010) African Trypanosomiasis Factsheet/ http://www.who.int/mediacentre/factsheets/fs259/en/.
3. Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E, (2011) Drug resistance in human African trypanosomiasis. Future Microbiol 6: 1037-1047.
4. Jacobs RT, Nare B, Phillips MA, (2011) State of the art in African trypanosome drug discovery. Curr Top Med Chem 11: 1255-1274.
5. Wyatt PG, Gilbert IH, Read KD, Fairlamb AH, (2011) Target validation: linking target and chemical properties to desired product profile. Curr Top Med Chem 11: 1275-1283.
6. DNDi HAT TPP, http://www.dndi.org/diseases/hat/target-product-profile.html.
7. Motyl M, Dorso K, Barrett J, Giacobbe R, (2006) Basic microbiological techniques used in antibacterial drug discovery. Curr Protoc Pharmacol Chapter 13: Unit13A 13.
8. Bahamontes-Rosa N, Rodriguez-Alejandre A, Gonzalez-del-Rio R, Garcia-Bustos JF, Mendoza-Losana A, (2012) A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels. Mol Biochem Parasitol 181: 171-177.
9. Chen YT, Brinen LS, Kerr ID, Hansell E, Doyle PS, et al. (2010) In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Negl Trop Dis 4: e825.
10. Jones DC, Hallyburton I, Stojanovski L, Read KD, Frearson JA, et al. (2010) Identification of a kappa-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem Pharmacol 80: 1478-1486.
11. Oduor RO, Ojo KK, Williams GP, Bertelli F, Mills J, et al. (2011) Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads. PLoS Negl Trop Dis 5: e1017.
12. Mercer L, Bowling T, Perales J, Freeman J, Nguyen T, et al. (2011) 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLoS Negl Trop Dis 5: e956.
13. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R, (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop 68: 139-147.
14. Sykes ML, Avery VM, (2009) Development of an Alamar Blue viability assay in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Am J Trop Med Hyg 81: 665-674.
15. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, et al. (2006) Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 67: 355-363.
16. Sykes ML, Avery VM, (2009) A luciferase based viability assay for ATP detection in 384-well format for high throughput whole cell screening of Trypanosoma brucei brucei bloodstream form strain 427. Parasit Vectors 2: 54.
17. Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, et al. (2010) N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464: 728-732.
18. Bacchi CJ, Garofalo J, Mockenhaupt D, McCann PP, Diekema KA, et al. (1983) In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol Biochem Parasitol 7: 209-225.
19. Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A, (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210: 332-334.
20. Carter NS, Berger BJ, Fairlamb AH, (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and-resistant Trypanosoma brucei brucei. J Biol Chem 270: 28153-28157.
21. Damper D, Patton CL, (1976) Pentamidine transport in Trypanosoma brucei- kinetics and specificity. Biochem Pharmacol 25: 271-276.